Rydoo, the Game-Changing Business Travel and Expense Mobile App That Eliminates Complicated Admin
World leader in Quality of Life services, Sodexo, together with Xpenditure and iAlbatros unveils Rydoo, the new platform that eliminates daily administrative tasks starting with business travel and expense management. Launched in France and worldwide today, Rydoo aims to unlock the full potential of a dynamic yet old-fashioned market, while supporting the digitization of workplaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180605006168/en/
A business traveler using Rydoo Travel (Photo: Rydoo)
At work, administrative tasks with no added value are frustrating. We have all spent hours searching for the right flight, queuing at hotel lobbies to check-out and then finally have confusing expense reports to fill in. No salesperson was ever hired to become an expert in travel arrangement or collecting paper receipts. Employees and companies deserve to focus on what matters and what offers value. Rydoo brings this technology to drive efficiency and enable better ways to work.
Now Rydoo reinvents and simplifies travel and expense management to just a few clicks and photos, whilst saving time and optimizing costs.
Game-Changing in Business Travel and Expense Management
Rydoo is the first platform to cover the full scope of any trip or any expense to contribute to a more fulfilling work environment. With an average adoption rate of 93% within the first month, Rydoo proves just how user-friendly it is for employees and efficient it is for companies.
As a result, finance teams in organizations benefit from:
- a 87% reduction in processing cost,
- sources of optimisation thanks to compliance with company policies
- time saving with expense processing time divided by 4
Rydoo is also a SaaS solution that takes just a few days to implement, releasing new features on a weekly basis. Rydoo has a competitive business model, starting at €6 per month/active user.
Rydoo combines a stellar user experience with corporate expectations
Rydoo’s end-to-end platform combines both worlds through two modules to streamline the entire business travel and expense process:
- Rydoo travel helps employees find the right flight, rail ticket or car rental, and book the hotel that suits their needs from among 800 000 accommodation choices, and offers a dashing user experience in less time. Rydoo travel skips the payment phase for employees (no more queuing at the lobby) thanks to central billing - finance teams receive a single invoice gathering all business travel-related information, at the end of the month.
- Rydoo expense allows employees to enjoy the snap-and-process feature that offers automated, paperless expense management while complying with company’s policy. Finance teams easily manage employees’ reimbursements in real-time and control the company’s expense budget.
- Using both modules guarantee full value from this new way of working, but companies can also start with one module, depending on their needs.
Rydoo, CEO, Sébastien Marchon, says : “Rydoo fights with daily life pain points at work by offering an end-user oriented app. Rydoo removes complexity for employees while offering 87% over time productivity for finance teams. By making Rydoo one of the leading players in the travel and expense market, Sodexo aims to improve the quality of life and performance of the organizations it serves.”
Sodexo Mobility & Expense, President, Didier Dumont, adds: “Keeping people efficiently on the move is essential for business success. Rydoo brings the Travel and Expense ecosystem together to gain time and real-time visibility for hassle-free performance. To deliver this to the market in an agile way, we define ourselves as a corp-up that combines the strength of a corporate company and the agility and innovative mindset of a start-up”.
Rydoo reinvents and simplifies business travel and expense management thanks of the expertise its two founding startups it is originated: Xpenditure and iAlbatros. With its 300 enthusiastic employees, Rydoo operates in more than 60 countries; its 6,000 customers (public and private organizations) benefit from the usability and efficiency of its consumer-oriented app. Rydoo is a Sodexo corp-up, the alliance of two startups and a large corporation.
Founded in 1966 by Pierre Bellon in Marseilles, France, Sodexo is the worldwide leader in Quality of Life services, an essential factor in the performance of individuals and organizations. Present in 80 countries, Sodexo delivers to 100 million customers a day a unique array of On-Site Services, Benefits and Rewards Services, and Personal and Home Services. With 50 years' experience covering more than 100 professions, Sodexo offers its clients a comprehensive range of services including hospitality, reception, cleaning, maintenance, technical equipment and facilities maintenance, staff motivation and incentivization, solutions to streamline and optimize personnel relocation and business expenses, as well as home help, daycare, and concierge services. Sodexo's success and performance relies on its independence, its sustainable economic model, and its ability to ensure the development and commitment of its 450,000 employees around the world. Sodexo is represented on the CAC 40 and DJSI indices.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45 | Tiedote
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10 | Tiedote
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme